Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Bayhill Therapeutics
About
Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics.
- 51 - 100
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $35.40M
- Industries
- Biopharma,Biotechnology,Therapeutics
- Founded date
- Jan 1, 2000
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 11, 2006 | Series Unknown | $15.80M | 2 | — | — | Detail |
| May 4, 2005 | Series B | $35.40M | 2 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series Unknown |
|
|
— | Series Unknown |
